5
Cresanto Global
RAYMEDLABSLTD NSE
Cresanto Global
HealthcareNSE: RAYMEDLABSLTD BSE: 531207 Pharmaceuticals & Biotechnology
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹2.20 Cr
P/E Ratio
-5.5
EBITDA
₹-0.30 Cr
Return on Equity
14.26%
Debt to Equity
0
Book Value
₹-7.08
52W High
₹5.12
52W Low
₹3.65
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
2- Company has low interest coverage ratio.
- Promoter holding is low: 32.3%
Growth Rate
Revenue Growth
-80%
Net Income Growth
100% lower than
3Y
Cash Flow Change
42.55% higher than
3Y
ROE
105% higher than
3Y
ROCE
324% higher than
3Y
EBITDA Margin (Avg.)
—
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.05 | 0 | 0 | 0 |
| Expenses | 0.01 | 0.02 | 0.02 | 0.05 | 0.02 | 0.02 | 0.26 | 0.34 | 0.09 | 0.06 | 0.11 | 0.08 | 0.06 |
| Operating Profit | -0.01 | -0.02 | -0.02 | -0.05 | -0.02 | -0.02 | -0.26 | -0.34 | -0.09 | -0.01 | -0.11 | -0.08 | -0.06 |
| OPM % | — | — | — | — | — | — | — | — | — | -20% | — | — | — |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.52 | 0 | 0 | 0.02 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.11 | 0 | 0 | 0 | 0.16 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | -0.01 | -0.02 | -0.02 | -0.05 | -0.02 | -0.02 | -0.25 | 0.07 | -0.09 | -0.01 | -0.09 | -0.24 | -0.06 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -0.02 | -0.02 | -0.02 | -0.05 | -0.02 | -0.02 | -0.25 | 0.07 | -0.09 | -0.01 | -0.09 | -0.24 | -0.06 |
| EPS in Rs | -0.05 | -0.05 | -0.05 | -0.12 | -0.05 | -0.05 | -0.59 | 0.16 | -0.21 | -0.02 | -0.21 | -0.56 | -0.14 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.05 | 0.05 |
| Expenses | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 | 0.06 | 0.07 | 0.08 | 0.19 | 0.1 | 0.6 | 0.34 | 0.31 |
| Operating Profit | -0.04 | -0.03 | -0.03 | -0.03 | -0.03 | -0.06 | -0.07 | -0.08 | -0.19 | -0.1 | -0.6 | -0.29 | -0.26 |
| OPM % | — | — | — | — | — | — | — | — | — | — | — | -580% | -520% |
| Other Income | 0.02 | 0 | -0.01 | -0.02 | -0.02 | 0.01 | 0.01 | 0 | 0.02 | 0 | 0.53 | 0.02 | 0.02 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.11 | 0.16 | 0.16 |
| Depreciation | 0 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 | 0 |
| PBT | -0.02 | -0.04 | -0.05 | -0.06 | -0.06 | -0.06 | -0.07 | -0.09 | -0.18 | -0.1 | -0.18 | -0.43 | -0.4 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
| Net Profit | -0.02 | -0.04 | -0.05 | -0.06 | -0.05 | -0.06 | -0.07 | -0.08 | -0.17 | -0.1 | -0.18 | -0.43 | -0.4 |
| EPS in Rs | -0.05 | -0.09 | -0.12 | -0.14 | -0.12 | -0.14 | -0.16 | -0.19 | -0.4 | -0.23 | -0.42 | -1.01 | -0.93 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 |
| Reserves | -6 | -6.04 | -6.09 | -6.15 | -6.2 | -6.26 | -6.33 | -6.41 | -6.58 | -6.68 | -6.86 | -7.29 |
| Borrowings | 2 | 1.99 | 2.03 | 2.04 | 2.05 | 2.07 | 2.21 | 0.05 | 0 | 2.43 | 2.37 | 2.81 |
| Other Liabilities | 0.04 | 0.06 | 0.07 | 0.11 | 0.14 | 0.18 | 0.1 | 2.33 | 2.47 | 0.13 | 0.25 | 0.22 |
| Total Liabilities | 0.31 | 0.28 | 0.28 | 0.27 | 0.26 | 0.26 | 0.25 | 0.24 | 0.16 | 0.15 | 0.03 | 0.01 |
| Fixed Assets | 0.2 | 0.19 | 0.19 | 0.18 | 0.17 | 0.17 | 0.16 | 0.16 | 0.15 | 0.15 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0.11 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.08 | 0.01 | 0 | 0.03 | 0.01 |
| Total Assets | 0.31 | 0.28 | 0.28 | 0.27 | 0.26 | 0.26 | 0.25 | 0.24 | 0.16 | 0.15 | 0.03 | 0.01 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -0.03 | 0.01 | 0 | 0 | 0 | 0 | 0 | -2.21 | -0.16 | -0.06 | -0.47 | -0.27 |
| Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.21 | 0.16 | 0.06 | 0.59 | 0.44 |
| Financing | 0.03 | -0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.11 | -0.16 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 |
| Free Cash Flow | -0.03 | 0.01 | 0 | 0 | 0 | 0 | 0 | -2.21 | -0.16 | -0.06 | 0.18 | -0.27 |
| CFO/OP | 75 | -33 | 0 | 0 | 0 | 0 | 0 | 2,762 | 84 | 60 | 78 | 93 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | — | — | — | — | — | — | — | — | — | — | — | 0 |
| Inventory Days | — | — | — | — | — | — | — | — | — | — | — | 0 |
| Cash Conversion Cycle | — | — | — | — | — | — | — | — | — | — | — | 0 |
| Working Capital Days | — | — | — | — | — | — | — | — | — | — | — | -1,606 |
| ROCE % | -7.84% | -8.16% | -13.95% | -16.22% | -21.43% | -60% | -60.87% | — | — | — | — | — |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Cresanto Global insights
60 extracted metrics + investor summaries across FY10–FY26.
Documents
1
Announcement under Regulation 30 (LODR)-Newspaper Publication
5 May - Newspaper Intimation for the Postal Ballot Notice 5 May - Newspaper Intimation for the Postal Ballot Notice
4
Board Meeting Outcome for Meeting Held On 28Th April, 2026
28 Apr - Board met on 28 Apr 2026; appointed new Company Secretary and proposed shifting office to Maharashtra. 28 Apr - Board met on 28 Apr 2026; appointed new Company Secretary and proposed shifting office to Maharashtra.
5
Appointment of Company Secretary and Compliance Officer
28 Apr - Board met on 28 Apr 2026, appointed Pooja Mandave and approved registered office shift, MOA alteration, postal ballot. 28 Apr - Board met on 28 Apr 2026, appointed Pooja Mandave and approved registered office shift, MOA alteration, postal ballot.
Frequently Asked Questions about Cresanto Global
What does Cresanto Global Limited do?
Incorporated in 1994, Cresanto Global Ltd is in the business of flexible packaging and trading
business.[1]
Where is Cresanto Global Limited (531207) listed?
Cresanto Global Limited trades as RAYMEDLABSLTD on the NSE and under code 531207 on the BSE.
Which sector does Cresanto Global Limited belong to?
Cresanto Global Limited is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Cresanto Global Limited?
Cresanto Global Limited has a market capitalisation of ₹2.2 Cr, which places it in the Small Cap band.
What is the PE ratio of Cresanto Global Limited?
Cresanto Global Limited trades at a PE ratio of -5.50, against a book value of ₹-7.08 per share.
What is the 52-week high and low of Cresanto Global Limited?
Over the last 52 weeks Cresanto Global Limited has traded between ₹3.65 and ₹5.12.
What is the Return on Equity (ROE) of Cresanto Global Limited?
Cresanto Global Limited reported a return on equity of 14.26%. Its debt-to-equity ratio is 0.00.
Company Information
Incorporated in 1994, Cresanto Global Ltd is in the business of flexible packaging and trading business.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531207.md for Cresanto Global Limited: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.